Physician profile
Lucky Ly
NPI 1639739113
$491.16
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $11.98 · 2021: $57.20 · 2022: $225 · 2023: $179 · 2024: $18.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $197.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $83.41 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $75.08 | 2023 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $70.56 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $48.47 | 2022-2023 | |
| Neurocrine Biosciences, INC. | $33.30 | 2023 | Ingrezza |
| Corium, LLC | $27.64 | 2022 | |
| Almatica Pharma LLC | $18.95 | 2022 | |
| Idorsia Pharmaceuticals US INC | $18.67 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $18.03 | 2024 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $17.08 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.62 | 2022 | |
| Janssen Pharmaceuticals, INC | $14.64 | 2021 | |
| Lundbeck LLC | $13.63 | 2022 | |
| Indivior INC. | $12.85 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.98 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $10.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lucky Ly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.